Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VM202 in peripheral artery disease
NCT03363165Phase 2Completed
- Sponsor
- Northwestern University
- Start
- Jan 2018
- Primary completion
- Feb 2023
- Modality
- Gene Editing, Gene Silencing, Plasmid DNA
- Countries
- 1
01
Overview
A Phase 2 trial of Engensis in peripheral artery disease (PAD), sponsored by Northwestern University. Started Jan 2018; status: completed.
02
Drugs
Engensis
03
Conditions
peripheral artery disease (PAD)
Beyond the preview
Go deeper on NCT03363165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03363165.